Home » Stocks » Annexon Biosciences

Annexon Biosciences, Inc. (ANNX)

Stock Price: $21.83 USD 2.60 (13.52%)
Updated Aug 5, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 786.07M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 31.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $21.83
Previous Close $19.23
Change ($) 2.60
Change (%) 13.52%
Day's Open 19.61
Day's Range 19.01 - 22.37
Day's Volume 291,834
52-Week Range 15.33 - 22.37

More Stats

Market Cap 786.07M
Enterprise Value 752.72M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 31.26M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 20.62
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 33.35M
Net Cash / Share 0.93
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE -117.24%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-32.52-19.15
Net Income-37.18-18.30
Shares Outstanding0.430.40
Earnings Per Share-88.30-45.89
Operating Cash Flow-28.36-17.19
Capital Expenditures-0.27-0.02
Free Cash Flow-28.63-17.21
Cash & Equivalents43.9344.18
Net Cash / Debt43.9344.18
Book Value-100-64.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Annexon Biosciences, Inc.
Country United States
Employees 30
CEO Douglas Love

Stock Information

Ticker Symbol ANNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ANNX
IPO Date July 24, 2020


Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.